Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
The Lancet (2022) Vol. 399, Iss. 10328, pp. 905-907
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
The staggering death toll of drug-resistant bacteria
Tosin Thompson
Nature (2022)
Closed Access | Times Cited: 106
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Laurent Rénia, Yun Shan Goh, Angéline Rouers, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Recent insights into SARS‐CoV‐2 omicron variant
Severino Jefferson Ribeiro da Silva, Alain Kohl, Lindomar Pena, et al.
Reviews in Medical Virology (2022) Vol. 33, Iss. 1
Open Access | Times Cited: 43
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium
Toni K. Choueiri, Chris Labaki, Ziad Bakouny, et al.
The Lancet Regional Health - Americas (2023) Vol. 19, pp. 100445-100445
Open Access | Times Cited: 31
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron
Maximilian J. Mair, Manfred Mitterer, Pia Gattinger, et al.
Cancer Cell (2022) Vol. 40, Iss. 5, pp. 444-446
Open Access | Times Cited: 35
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review
Vanessa Piechotta, Sibylle C. Mellinghoff, Caroline Hirsch, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 5
Open Access | Times Cited: 31
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
Firas El Chaer, Jeffery J. Auletta, Roy F. Chemaly
Blood (2022) Vol. 140, Iss. 7, pp. 673-684
Open Access | Times Cited: 28
Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine
Nikolai Petrovsky
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 5
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics
Giulia Dowgier, Agnieszka Hobbs, David Greenwood, et al.
Vaccine (2025) Vol. 54, pp. 126960-126960
Closed Access
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
Sjoukje F. Oosting, Astrid A.M. van der Veldt, Rudolf S.N. Fehrmann, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 7, pp. 833-835
Open Access | Times Cited: 25
Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study
Adrian M. Shields, Sian Faustini, Harriet J. Hill, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 10, pp. 100781-100781
Open Access | Times Cited: 22
Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era
Jérémie Zerbit, Marion Detroit, Antoine Meyer, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2377-2377
Open Access | Times Cited: 22
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
Andrés Chang, Jean L. Koff, Lilin Lai, et al.
Blood Advances (2023) Vol. 7, Iss. 11, pp. 2459-2462
Open Access | Times Cited: 12
The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases
Sruthi Vijaya Retnakumar, Camille Chauvin, Jagadeesh Bayry
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108399-108399
Open Access | Times Cited: 12
Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study
Lance Turtle, Sarah Elliot, Thomas M Drake, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 5, pp. 636-648
Open Access | Times Cited: 4
Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
Lee M. Greenberger, Larry A. Saltzman, Lore Gruenbaum, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 6, pp. 481-489
Open Access | Times Cited: 21
Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters
Sapna Sharma, Thomas Vercruysse, Lorena Sanchez‐Felipe, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 20
Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer
Thomas Lehrnbecher, Ulrich Sack, Carsten Speckmann, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e510-e513
Open Access | Times Cited: 19
Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
Helen Kakkassery, Esme Carpenter, Piers Patten, et al.
Trends in Molecular Medicine (2022) Vol. 28, Iss. 12, pp. 1082-1099
Open Access | Times Cited: 18
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations
Francesco Passamonti, Emanuele Nicastri, Alice Di Rocco, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 3-15
Open Access | Times Cited: 18
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
Carolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5512-5512
Open Access | Times Cited: 18
Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant
Fabian Ullrich, Christine Hanoun, Amin T. Turki, et al.
European Journal Of Haematology (2022) Vol. 109, Iss. 4, pp. 364-372
Open Access | Times Cited: 17
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
Paola Storti, Valentina Marchica, Rosanna Vescovini, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top